Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Drops By 90.2%

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 122,900 shares, a decrease of 90.2% from the January 15th total of 1,260,000 shares. Based on an average daily trading volume, of 208,100 shares, the days-to-cover ratio is presently 0.6 days. Approximately 3.3% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on BLRX shares. StockNews.com assumed coverage on BioLineRx in a report on Tuesday, February 4th. They issued a “hold” rating for the company. HC Wainwright decreased their target price on shares of BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a research note on Monday, November 25th.

BioLineRx Price Performance

BLRX stock traded down $0.06 during mid-day trading on Thursday, reaching $3.47. 36,272 shares of the company’s stock were exchanged, compared to its average volume of 419,266. BioLineRx has a 12-month low of $3.24 and a 12-month high of $57.60. The stock’s 50 day moving average is $6.46 and its 200 day moving average is $16.50. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. The company has a market cap of $6.93 million, a price-to-earnings ratio of -0.39 and a beta of 1.41.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($2.80) EPS for the quarter, beating the consensus estimate of ($3.20) by $0.40. BioLineRx had a negative return on equity of 163.37% and a negative net margin of 90.57%. On average, research analysts expect that BioLineRx will post -5.8 EPS for the current year.

Institutional Trading of BioLineRx

An institutional investor recently raised its position in BioLineRx stock. Atria Investments Inc grew its stake in BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 133,974 shares of the biotechnology company’s stock after purchasing an additional 29,193 shares during the period. Atria Investments Inc owned approximately 0.17% of BioLineRx worth $72,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.